Full Press Release Details
Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY Endovascular Robotic Surgical System
evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system
Mass., August 1, 2024 - Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University,
which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics
in endovascular procedures. Under the terms of the agreement, Emory University will assume the responsibility of exploring the feasibility
of integrating the LIBERTY Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic
system for endovascular procedures. Amir Pourmorteza, PhD, Assistant Professor in the Department of Radiology and Imaging Sciences at
Emory University Winship Cancer Institute, and Department of Biomedical Engineering at Georgia Institute of Technology, will lead the
evaluation under Project Trita.
robotics has the potential to standardize outcomes, improve efficiencies, reduce radiation exposure, and democratize access to top-level
healthcare," commented Dr. Pourmorteza. "Project Trita merges CT-guidance, artificial intelligence, and medical Robotics.
I am excited to work with Microbot Medical on this project."
vision for the future of endovascular robotics includes autonomous capabilities, which has the potential to standardize endovascular
procedures and improve access to benefit millions of patients globally. We believe LIBERTY can be integrated with imaging,
planning and navigation software to ultimately create an autonomous robotic system that can be used in endovascular procedures,"
said Harel Gadot, CEO, President and Chairman of Microbot Medical. "We're excited to work with Dr. Pourmorteza who is a leader
in this space and we believe he shares a similar vision."
Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
Investigational LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used
in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation
exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System's remote operation
has the potential to be the first system to democratize endovascular interventional procedures.
information about Microbot Medical is available at
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY
Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether
the Company's pivotal study in humans is successful, any failure or inability to recruit physicians and clinicians to serve as
primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new
and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from
the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports
filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.